102 related articles for article (PubMed ID: 32082491)
21. Correction:
Holien T; Misund K; Olsen OE; Baranowska KA; Buene G; Børset M; Waage A; Sundan A
Oncotarget; 2018 Nov; 9(89):36048. PubMed ID: 30542518
[TBL] [Abstract][Full Text] [Related]
22. Correction: Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes.
Cedena MT; Rapado I; Santos-Lozano A; Ayala R; Onecha E; Abaigar M; Such E; Ramos F; Cervera J; Díez-Campelo M; Sanz G; Rivas JH; Lucía A; Martínez-López J
Oncotarget; 2018 Jul; 9(56):30936. PubMed ID: 30112119
[TBL] [Abstract][Full Text] [Related]
23. Mutant E-cadherin breast cancer cells do not display constitutive Wnt signaling.
van de Wetering M; Barker N; Harkes IC; van der Heyden M; Dijk NJ; Hollestelle A; Klijn JG; Clevers H; Schutte M
Cancer Res; 2001 Jan; 61(1):278-84. PubMed ID: 11196175
[TBL] [Abstract][Full Text] [Related]
24. Cancer stemness in Wnt-driven mammary tumorigenesis.
Monteiro J; Gaspar C; Richer W; Franken PF; Sacchetti A; Joosten R; Idali A; Brandao J; Decraene C; Fodde R
Carcinogenesis; 2014 Jan; 35(1):2-13. PubMed ID: 23955540
[TBL] [Abstract][Full Text] [Related]
25. Correction: COTI-2, a novel small molecule that is active against multiple human cancer cell lines
Salim KY; Vareki SM; Danter WR; San-Marina S; Koropatnick J
Oncotarget; 2017 Sep; 8(36):60724. PubMed ID: 29062467
[TBL] [Abstract][Full Text] [Related]
26. Correction: Enhanced tumorigenicity by mitochondrial DNA mild mutations.
Cruz-Bermúdez A; Vallejo CG; Vicente-Blanco RJ; Gallardo ME; Fernández-Moreno MÁ; Quintanilla M; Garesse R
Oncotarget; 2020 Mar; 11(11):1006. PubMed ID: 32215189
[TBL] [Abstract][Full Text] [Related]
27. Correction: Reversion of resistance to oxaliplatin by inhibition of p38 MAPK in colorectal cancer cell lines: involvement of the calpain / Nox1 pathway.
Chocry M; Leloup L; Kovacic H
Oncotarget; 2018 Jun; 9(42):26978-26979. PubMed ID: 29928496
[TBL] [Abstract][Full Text] [Related]
28. HOXD3 Plays a Critical Role in Breast Cancer Stemness and Drug Resistance.
Zhang Y; Zhang Q; Cao Z; Huang Y; Cheng S; Pang D
Cell Physiol Biochem; 2018; 46(4):1737-1747. PubMed ID: 29698974
[TBL] [Abstract][Full Text] [Related]
29. Correction: Germline mutations in the oncogene EZH2 cause Weaver syndrome and increased human height.
Tatton-Brown K; Hanks S; Ruark E; Zachariou A; Del Vecchio Duarte S; Ramsay E; Snape K; Murray A; Perdeaux ER; Seal S; Loveday C; Banka S; Clericuzio C; Flinter F; Magee A; McConnell V; Patton M; Raith W; Rankin J; Splitt M; Strenger V; Taylor C; Wheeler P; Temple IK; Cole T; ; Douglas J; Rahman N
Oncotarget; 2018 Nov; 9(94):36719. PubMed ID: 30613354
[TBL] [Abstract][Full Text] [Related]
30. Correction: Recurrent mutations in a
Zeng W; Hu B; Tang L; You YY; Toderici M; Eugenia de la Morena-Barrio M; Corral J; Hu Y
Oncotarget; 2018 Feb; 9(13):11428. PubMed ID: 29542734
[TBL] [Abstract][Full Text] [Related]
31. cDNA microarray profiles of canine mammary tumour cell lines reveal deregulated pathways pertaining to their phenotype.
Rao NA; van Wolferen ME; van den Ham R; van Leenen D; Groot Koerkamp MJ; Holstege FC; Mol JA
Anim Genet; 2008 Aug; 39(4):333-45. PubMed ID: 18462483
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of Id1 in transgenic mice promotes mammary basal stem cell activity and breast tumorigenesis.
Shin DH; Park JH; Lee JY; Won HY; Jang KS; Min KW; Jang SH; Woo JK; Oh SH; Kong G
Oncotarget; 2015 Jul; 6(19):17276-90. PubMed ID: 25938540
[TBL] [Abstract][Full Text] [Related]
33. Correction: The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity
Shi F; Zhang J; Liu H; Wu L; Jiang H; Wu Q; Liu T; Lou M; Wu H
Oncotarget; 2018 Mar; 9(24):17255. PubMed ID: 29683149
[TBL] [Abstract][Full Text] [Related]
34. Wnt-1 and int-2 mammary oncogene effects on the beta-catenin pathway in immortalized mouse mammary epithelial cells are not sufficient for tumorigenesis.
Hollmann CA; Kittrell FS; Medina D; Butel JS
Oncogene; 2001 Nov; 20(52):7645-57. PubMed ID: 11753642
[TBL] [Abstract][Full Text] [Related]
35. Correction:
Madic J; Jovelet C; Lopez J; André B; Fatien J; Miran I; Honoré A; Mezquita L; Besse B; Lacroix L; Droniou M
Oncotarget; 2019 Feb; 10(13):1345. PubMed ID: 30863495
[TBL] [Abstract][Full Text] [Related]
36. Correction: The mutational landscape of ocular marginal zone lymphoma identifies frequent alterations in
Jung H; Yoo HY; Lee SH; Shin S; Kim SC; Lee S; Joung JG; Nam JY; Ryu D; Yun JW; Choi JK; Ghosh A; Kim KK; Kim SJ; Kim WS; Park WY; Ko YH
Oncotarget; 2018 Aug; 9(67):32882. PubMed ID: 30214692
[TBL] [Abstract][Full Text] [Related]
37. Correction: The investigation of transcriptional repression mediated by ZEB2 in canine invasive micropapillary carcinoma in mammary gland.
Gamba CO; Damasceno KA; Ferreira IC; Rodrigues MA; Gomes DA; Alves MR; Rocha RM; Lima AE; Ferreira E; Cassali GD
PLoS One; 2019; 14(3):e0214567. PubMed ID: 30908537
[TBL] [Abstract][Full Text] [Related]
38. Correction: Aryl hydrocarbon receptor regulates histone deacetylase 8 expression to repress tumor suppressive activity in hepatocellular carcinoma.
Wang LT; Chiou SS; Chai CY; Hsi E; Wang SN; Huang SK; Hsu SH
Oncotarget; 2018 Dec; 9(102):37807. PubMed ID: 30701034
[TBL] [Abstract][Full Text] [Related]
39. Correction: Circulating and tumor-associated caspase-4: a novel diagnostic and prognostic biomarker for non-small cell lung cancer.
Terlizzi M; Colarusso C; De Rosa I; De Rosa N; Somma P; Curcio C; Sanduzzi A; Micheli P; Molino A; Saccomanno A; Salvi R; Aquino RP; Pinto A; Sorrentino R
Oncotarget; 2018 Jun; 9(50):29537. PubMed ID: 30034638
[TBL] [Abstract][Full Text] [Related]
40. Expression of the oncogene c-erbB-2 in canine mammary cancers and tumor-derived cell lines.
Ahern TE; Bird RC; Bird AE; Wolfe LG
Am J Vet Res; 1996 May; 57(5):693-6. PubMed ID: 8723884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
